SEC Tracker
Get the app

Autolus Therapeutics AUTL

Autolus Therapeutics Q3 FY23: net loss $45.8M; diluted EPS −$0.26

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract

Key figures from this report

These are the numbers Autolus Therapeutics reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$45.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.26No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$256.4MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$40.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Autolus Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Savara SVRA public float $544M, Jun 30, 2025
  2. Carisma Therapeutics CARM
  3. Xencor XNCR public float $556M, Jun 30, 2025
  4. Opko Health OPK public float $540M, Dec 31, 2025
  5. Evolus EOLS public float $560M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.